Edwards Lifesciences Corp. 10-Q Summary: Q3 2025
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. Edwards Lifesciences is a global leader in structural heart disease innovation. The company recently completed the sale of its Critical Care product group (classified as discontinued operations) and has entered a definitive agreement to sell a non-core product group, expected to close in Q4 2025. The company operates in four geographic segments: United States, Europe, Japan, and Rest of World.
Key Financial Metrics
| Metric | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Net Sales | $1,553.1M | $1,354.4M | $4,498.0M | $4,053.7M |
| Gross Profit | $1,207.9M | $1,091.5M | $3,506.8M | $3,228.4M |
| Operating Income | $307.1M | $350.6M | $1,113.1M | $1,066.1M |
| Net Income (Continuing Ops) | $292.3M | $362.1M | $991.8M | $1,051.0M |
| Diluted EPS (Continuing Ops) | $0.50 | $0.61 | $1.70 | $1.75 |
| Cash & Equivalents | $2,685.6M | (Balance Sheet Data) | ||
| Short-term Investments | $1,156.4M | (Balance Sheet Data) | ||
| Long-term Debt | $598.2M | (Balance Sheet Data) | ||
| Operating Cash Flow (9M) | N/A | $1,144.3M | $669.8M |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14.7% in Q3 2025 and 11.0% for the nine months ended September 30, 2025, compared to the prior year. Growth was driven by Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT).
- Profitability Pressure: Despite revenue growth, operating income decreased 12.4% in Q3 2025. This was primarily due to a significant increase in litigation expenses ($90.4M in Q3 2025 vs. $10.8M in Q3 2024) and a $40.0M intangible asset impairment charge.
- Discontinued Operations: Q3 2024 results included a massive one-time gain of $2.7B from the sale of the Critical Care business. Q3 2025 reflects a small loss of $2.0M from discontinued operations, making year-over-year comparisons of total net income misleading.
- Share Repurchases: The company repurchased 11.2 million shares for $844.9M in the first nine months of 2025, including $750M in accelerated share repurchase (ASR) agreements.
Guidance, Outlook, and Risks
- Outlook: Management expects continued growth in TAVR and TMTT segments. The company is evaluating the impact of new U.S. trade policies and tariffs on its supply chain and demand.
- Tax Risks: The effective tax rate for continuing operations rose to 16.1% in Q3 2025 (from 10.1% in Q3 2024) due to global minimum tax (Pillar Two) and reduced tax benefits from share-based compensation. The company expects an additional $50M in tax expense in 2025 due to Pillar Two.
- Legal Contingencies: Significant litigation expenses were incurred related to intellectual property disputes (Aortic Innovations) and tax litigation. The company has accrued $85.5M for legal proceedings as of September 30, 2025. A major IRS dispute regarding transfer pricing for 2015-2017 tax years remains unresolved, with the company contesting a proposed deficiency of approximately $269.3M.
- Acquisitions: The FTC moved to block the proposed acquisition of JenaValve in August 2025; the company expects a final court determination by Q1 2026.
Investor Verification Checklist
- Litigation Exposure: Verify the status and potential financial impact of the Aortic Innovations patent litigation and the ongoing IRS transfer pricing dispute.
- Discontinued Operations: Confirm that Q3 2024 earnings comparisons exclude the $2.7B gain from the Critical Care sale to assess true organic performance.
- Intangible Impairment: Review the details of the $40.0M impairment charge regarding developed technology assets to understand future R&D pipeline risks.
- Tax Rate Volatility: Monitor the impact of global minimum tax (Pillar Two) and the resolution of the IRS audit on future effective tax rates.
- Regulatory Approvals: Track the outcome of the FTC challenge to the JenaValve acquisition and the status of the non-core product group sale expected in Q4 2025.